Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy in Metastatic Renal Cell Carcinoma
NCT02926053Phase 1Completed
- Start
- Dec 2016
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in metastatic renal cell carcinoma (mRCC). Primary endpoint: Number of Patients in Which the Treatment Was Tolerable. Started Dec 2016; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02926053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926053.